{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:44Z","timestamp":1789972124331,"version":"4.0.1"},"reference-count":43,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:p>Bisphosphonates are effective for preventing and treating skeletal disorders associated with hyperresorption. Their safety and efficacy has been studied in adults where the growth plate is fused and there is no longitudinal bone growth and little appositional growth. Although bisphosphonate use in the pediatric population was pioneered for compassionate use in the treatment of osteogenesis imperfecta, they are being increasingly used for the treatment and prevention of bone loss in children at risk of hyperresorptive bone loss. However, the effect of these agents on the growing skeleton in disorders other than osteogenesis imperfecta has not been systematically compared. Studies were, therefore, undertaken to examine the consequences of bisphosphonate administration on the growth plate and skeletal microarchitecture during a period of rapid growth. C57Bl6\/J male mice were treated from 18 to 38 days of age with vehicle, alendronate, pamidronate, zoledronate, or clodronate at doses selected to replicate those used in humans. Treatment with alendronate, pamidronate, and zoledronate, but not clodronate, led to a decrease in the number of chondrocytes per column in the hypertrophic chondrocyte layer. This was not associated with altered hypertrophic chondrocyte apoptosis or vascular invasion at the growth plate. The effects of pamidronate on trabecular microarchitecture were less beneficial than those of alendronate and zoledronate. Pamidronate did not increase cortical thickness or cortical area\/total area relative to control mice. These studies suggest that bisphosphonate administration does not adversely affect skeletal growth. Long-term investigations are required to determine whether the differences observed among the agents examined impact biomechanical integrity of the growing skeleton.<\/jats:p>","DOI":"10.1210\/en.2013-1993","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T19:52:42Z","timestamp":1389729162000},"page":"1188-1196","source":"Crossref","is-referenced-by-count":27,"title":["Effect of Bisphosphonates on the Rapidly Growing Male Murine Skeleton"],"prefix":"10.1210","volume":"155","author":[{"given":"Eric D.","family":"Zhu","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeann","family":"Louis","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Brooks","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Bouxsein","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie B.","family":"Demay","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071611550315400_B1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase iii osteoporosis treatment study group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071611550315400_B3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (vert) study group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2020071611550315400_B4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071611550315400_B5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071611550315400_B6","first-page":"CD005324","article-title":"Bisphosphonate therapy for children and adolescents with secondary osteoporosis","author":"Ward","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2020071611550315400_B7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1067\/mpd.2002.128207","article-title":"Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial","volume":"141","author":"Henderson","year":"2002","journal-title":"J Pediatr"},{"key":"2020071611550315400_B8","first-page":"179","article-title":"Bone status evaluation with calcaneal ultrasound in children with chronic rheumatic diseases. A one year followup study","volume":"30","author":"Falcini","year":"2003","journal-title":"J Rheumatol"},{"key":"2020071611550315400_B9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00467-008-0940-9","article-title":"Bisphosphonates in children with hypercalciuria and reduced bone mineral density","volume":"23","author":"Freundlich","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"2020071611550315400_B10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000329151","article-title":"Bisphosphonate therapy in children with secondary osteoporosis","volume":"76","author":"Papapoulos","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"2020071611550315400_B11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2106\/00004623-199404000-00011","article-title":"Undiagnosed fractures in severely injured children and young adults. Identification with technetium imaging","volume":"76","author":"Heinrich","year":"1994","journal-title":"J Bone Joint Surg Am"},{"key":"2020071611550315400_B12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1359\/jbmr.070318","article-title":"Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair","volume":"22","author":"Amanat","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis","volume":"19","author":"Rauch","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B14","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1073\/pnas.0502249102","article-title":"Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes","volume":"102","author":"Sabbagh","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611550315400_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(00)00409-9","article-title":"Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism","volume":"28","author":"Mansfield","year":"2001","journal-title":"Bone"},{"key":"2020071611550315400_B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02547218","article-title":"Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone","volume":"11","author":"Russell","year":"1973","journal-title":"Calcif Tissue Res"},{"key":"2020071611550315400_B17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02547219","article-title":"Effect of ethane-1-hydroxy-1,1-diphosphonate (ehdp) and dichloromethylene diphosphonate (cl 2 mdp) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats","volume":"11","author":"Schenk","year":"1973","journal-title":"Calcif Tissue Res"},{"key":"2020071611550315400_B18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S8756-3282(02)00974-2","article-title":"Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta","volume":"32","author":"Evans","year":"2003","journal-title":"Bone"},{"key":"2020071611550315400_B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/JPEM.2005.18.1.43","article-title":"A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta","volume":"18","author":"Dimeglio","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071611550315400_B20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types iii and iv osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B22","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type i","volume":"90","author":"Ward","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611550315400_B23","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B24","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","article-title":"Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types i, iii, and iv","volume":"111","author":"Zeitlin","year":"2003","journal-title":"Pediatrics"},{"key":"2020071611550315400_B25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/JBMR.050213","article-title":"Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome","volume":"20","author":"Munns","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00431-004-1541-7","article-title":"Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis","volume":"164","author":"Melchior","year":"2005","journal-title":"Eur J Pediatr"},{"key":"2020071611550315400_B27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00774-009-0149-4","article-title":"Response to zolendronic acid in children with type iii osteogenesis imperfecta","volume":"28","author":"Panigrahi","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"2020071611550315400_B28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0945-053X(94)90199-6","article-title":"Characterization of primary cultures of chondrocytes from type II collagen\/\u03b2-galactosidase transgenic mice","volume":"14","author":"Lefebvre","year":"1994","journal-title":"Matrix Biol"},{"key":"2020071611550315400_B29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S8756-3282(02)00841-4","article-title":"The absolute bioavailability of clodronate from two different oral doses","volume":"31","author":"Villikka","year":"2002","journal-title":"Bone"},{"key":"2020071611550315400_B30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model","volume":"52","author":"McCarthy","year":"2002","journal-title":"Pediatr Res"},{"key":"2020071611550315400_B31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.bone.2011.07.031","article-title":"Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis","volume":"49","author":"Simm","year":"2011","journal-title":"Bone"},{"key":"2020071611550315400_B32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/MCB.00617-07","article-title":"A-raf and b-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes","volume":"28","author":"Provot","year":"2008","journal-title":"Mol Cell Biol"},{"key":"2020071611550315400_B33","doi-asserted-by":"crossref","first-page":"18270","DOI":"10.1074\/jbc.M109.098616","article-title":"Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon erk1\/2 phosphorylation","volume":"285","author":"Miedlich","year":"2010","journal-title":"J Biol Chem"},{"key":"2020071611550315400_B34","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1210\/en.2002-220454","article-title":"Rickets in vdr null mice is secondary to decreased apoptosis of hypertrophic chondrocytes","volume":"143","author":"Donohue","year":"2002","journal-title":"Endocrinology"},{"key":"2020071611550315400_B35","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2020071611550315400_B36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/(SICI)1097-4652(199906)179:3<276::AID-JCP5>3.0.CO;2-#","article-title":"Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes","volume":"179","author":"Mansfield","year":"1999","journal-title":"J Cell Physiol"},{"key":"2020071611550315400_B37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets mmp-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"2020071611550315400_B38","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0024-3205(03)00657-X","article-title":"Regulation of mmp-9 (gelatinase b) in activated human monocyte\/macrophages by two different types of bisphosphonates","volume":"73","author":"Valleala","year":"2003","journal-title":"Life Sci"},{"key":"2020071611550315400_B39","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ar.21092","article-title":"Alendronate affects cartilage resorption by regulating vascular endothelial growth factor expression in rats","volume":"293","author":"Kang","year":"2010","journal-title":"Anat Rec (Hoboken)"},{"key":"2020071611550315400_B40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1439-0264.2008.00920.x","article-title":"Effects of alendronate on a disintegrin and metalloproteinase with thrombospondin motifs expression in the developing epiphyseal cartilage in rats","volume":"38","author":"Kim","year":"2009","journal-title":"Anat Histol Embryol"},{"key":"2020071611550315400_B41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"2020071611550315400_B42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/jpem.2011.182","article-title":"Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens","volume":"24","author":"Martinez-Soto","year":"2011","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071611550315400_B43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/155\/4\/1188\/10825244\/endo1188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/155\/4\/1188\/10825244\/endo1188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T17:58:11Z","timestamp":1594922291000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/155\/4\/1188\/2423006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2013-1993","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]}}}